R&D is the first stage in the market's value chain. These items need extensive research and development. R&D efforts are classified into two categories: in-house and outsourced work. In-house responsibilities are concentrated on crucial processes including basic analysis and electronic interpretation of testing parameters. The primary stakeholders in the gene editing supply chain include prominent firms offering gene editing products and services, SMEs, distributors, and end clients (pharmaceutical & biotechnology corporations, academic & research institutions, and diagnostic companies). The primary market influences are investors/funders.
The prominent players in the global gene editing market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US).
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Genome Editing/Genome Engineering Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Genome Editing/Genome Engineering Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Genome Editing/Genome Engineering Market based on Application
• Cell line engineering
• Genetic Engineering
• Drug Discovery
• Gene-modified cell therapy and Diagnostics
• Other Applications
Genome Editing/Genome Engineering Market based on Technology
• CRISPR
• TALEN
• ZFN
• Other technologies
Genome Editing/Genome Engineering Market based on End User
• Academics & Government Institutes
• Biotechnology & Pharma Companies
• Contract Research Organizations
Genome Editing/Genome Engineering Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The worldwide genome editing market is divided into four sections: application, technology, end user, and geography. The market is further divided by application into cell line engineering, genetic engineering, drug discovery, gene modified cell therapy & diagnostics, and other applications. CRISPR, TALEN, ZFN, and other technologies are classified as CRISPR technologies. End users are classified as academics and government institutes, biotechnology and pharmaceutical businesses, and contract research organisations. The market is divided into four regions: North America, Europe, Asia-Pacific, and Latin America and the Caribbean.
In 2020, the CRISPR category accounted for the greatest proportion of the genome editing market by technology. The simplicity of usage associated with CRISPR, which offers it a major edge over ZFN and TALEN, accounts for a large part of this category. In 2020, pharmaceutical firms held the greatest proportion of the genome editing market. The rising frequency of infectious illnesses and cancer is fueling global research efforts. This will increase demand for genome editing in biotechnology and pharmaceutical businesses.
During the forecast period, North America is expected to account for a sizable portion of the worldwide genome editing market. The region's market is expected to grow in the future, owing to the development of gene therapy in the United States, an increase in the use of genetically modified crops, an increase in the prevalence of infectious diseases and cancer, and the availability of research grants and funding.
Agilent Technologies, CRISPR Therapeutics, Danaher, Eurofins Scientific, Editas Medicine, GenScript, Horizon Discovery Limited, Lonza, Merck, and Thermo Fisher Scientific are among the prominent industry participants mentioned in the study.
• This report illustrates the most vital attributes of the Genome Editing/Genome Engineering Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Genome Editing/Genome Engineering Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Genome Editing/Genome Engineering Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Genome Editing/Genome Engineering Market.
Table of Contents 1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Application: Market Size & Analysis 5.1. Overview 5.2. Cell line engineering 5.3. Genetic Engineering 5.4. Drug Discovery 5.5. Gene-modified cell therapy and Diagnostics 5.6. Other Applications 6. Technology: Market Size & Analysis 6.1. Overview 6.2. CRISPR 6.3. TALEN 6.4. ZFN 6.5. Other technologies 7. End User: Market Size & Analysis 7.1. Overview 7.2. Academics & Government Institutes 7.3. Biotechnology & Pharma Companies 7.4. Contract Research Organizations 8. Geography: Market Size & Analysis 8.1. Overview 8.2. North America (U.S., Mexico, Canada) 8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 8.5. Latin America (Brazil, Argentina) 8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 9. Competitive Landscape 9.1. Competitor Comparison Analysis 9.2. Market Developments 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 9.2.2. Product Launches and execution 10. Vendor Profiles 10.1. GENSCRIPT BIOTECH CORPORATION 10.1.1. Overview 10.1.2. Financial Overview 10.1.3. Product Offerings 10.1.4. Developments 10.1.5. Business Strategy 10.2. AGLIENT TECHNOLOGIES, INC. 10.2.1. Overview 10.2.2. Financial Overview 10.2.3. Product Offerings 10.2.4. Developments 10.2.5. Business Strategy 10.3. MERCK KGAA 10.3.1. Overview 10.3.2. Financial Overview 10.3.3. Product Offerings 10.3.4. Developments 10.3.5. Business Strategy 10.4. EDITAS MEDICINE, INC 10.4.1. Overview 10.4.2. Financial Overview 10.4.3. Product Offerings 10.4.4. Developments 10.4.5. Business Strategy 10.5. DANAHER CORPORATION 10.5.1. Overview 10.5.2. Financial Overview 10.5.3. Product Offerings 10.5.4. Developments 10.5.5. Business Strategy 10.6. CRISPR THERAPEUTICS AG 10.6.1. Overview 10.6.2. Financial Overview 10.6.3. Product Offerings 10.6.4. Developments 10.6.5. Business Strategy 10.7. LONZA GROUP LTD. 10.7.1. Overview 10.7.2. Financial Overview 10.7.3. Product Offerings 10.7.4. Developments 10.7.5. Business Strategy 10.8. THERMO FISHER SCIENTIFIC, INC. 10.8.1. Overview 10.8.2. Financial Overview 10.8.3. Product Offerings 10.8.4. Developments 10.8.5. Business Strategy 10.9. ORIGENE TECHNOLOGIES 10.9.1. Overview 10.9.2. Financial Overview 10.9.3. Product Offerings 10.9.4. Developments 10.9.5. Business Strategy 10.10. EUROFINS SCIENTIFIC 10.10.1. Overview 10.10.2. Financial Overview 10.10.3. Product Offerings 10.10.4. Developments 10.10.5. Business Strategy 11. Analyst Opinion 12. Annexure 12.1. Report Scope 12.2. Market Definitions 12.3. Research Methodology 12.3.1. Data Collation and In-house Estimation 12.3.2. Market Triangulation 12.3.3. Forecasting 12.4. Report Assumptions 12.5. Declarations 12.6. Stakeholders 12.7. Abbreviations
Tables TABLE 1. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 2. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CRISPR, BY GEOGRAPHY , 2021-2030 (USD BILLION) TABLE 3. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR TALEN, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR ZFN, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 5. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 6. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CELL LINE ENGINEERING, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR GENETIC ENGINEERING, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR DRUG DISCOVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 9. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR GENE-MODIFIED CELL THERAPY AND DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 11. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 12. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR ACADEMICS & GOVERNMENT INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 13. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 14. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CONTRACT RESEARCH ORGANIZATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 15. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 16. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 17. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 18. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 19. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 20. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 21. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 22. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 23. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 24. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 25. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 26. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 27. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 28. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 29. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 30. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 31. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 32. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 33. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 34. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 35. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 36. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 37. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 38. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 39. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 40. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 41. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 42. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 43. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 44. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 45. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 46. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 47. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 48. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 49. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 50. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 51. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 52. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 53. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 54. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 55. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 56. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 57. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 58. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 59. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 60. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 61. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 62. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 63. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 64. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 65. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 66. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 67. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 68. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 69. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 70. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 71. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 72. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 73. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 74. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 75. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 76. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 77. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 78. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 79. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 80. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 81. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 82. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 83. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 84. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 85. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 86. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 87. GENSCRIPT BIOTECH CORPORATION : FINANCIALS TABLE 88. GENSCRIPT BIOTECH CORPORATION : PRODUCTS & SERVICES TABLE 89. GENSCRIPT BIOTECH CORPORATION : RECENT DEVELOPMENTS TABLE 90. AGLIENT TECHNOLOGIES, INC.: FINANCIALS TABLE 91. AGLIENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES TABLE 92. AGLIENT TECHNOLOGIES, INC.: RECENT DEVELOPMENTS TABLE 93. MERCK KGAA: FINANCIALS TABLE 94. MERCK KGAA: PRODUCTS & SERVICES TABLE 95. MERCK KGAA: RECENT DEVELOPMENTS TABLE 96. EDITAS MEDICINE, INC: FINANCIALS TABLE 97. EDITAS MEDICINE, INC: PRODUCTS & SERVICES TABLE 98. EDITAS MEDICINE, INC: RECENT DEVELOPMENTS TABLE 99. DANAHER CORPORATION: FINANCIALS TABLE 100. DANAHER CORPORATION: PRODUCTS & SERVICES TABLE 101. DANAHER CORPORATION: RECENT DEVELOPMENTS TABLE 102. CRISPR THERAPEUTICS AG: FINANCIALS TABLE 103. CRISPR THERAPEUTICS AG: PRODUCTS & SERVICES TABLE 104. CRISPR THERAPEUTICS AG: RECENT DEVELOPMENTS TABLE 105. LONZA GROUP LTD.: FINANCIALS TABLE 106. LONZA GROUP LTD.: PRODUCTS & SERVICES TABLE 107. LONZA GROUP LTD.: DEVELOPMENTS TABLE 108. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS TABLE 109. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES TABLE 110. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS TABLE 111. ORIGENE TECHNOLOGIES: FINANCIALS TABLE 112. ORIGENE TECHNOLOGIES: PRODUCTS & SERVICES TABLE 113. ORIGENE TECHNOLOGIES: RECENT DEVELOPMENTS TABLE 114. EUROFINS SCIENTIFIC: FINANCIALS TABLE 115. EUROFINS SCIENTIFIC: PRODUCTS & SERVICES TABLE 116. EUROFINS SCIENTIFIC: RECENT DEVELOPMENTS Charts CHART. 1. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 2. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CRISPR, BY GEOGRAPHY , 2021-2030 (USD BILLION) CHART. 3. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR TALEN, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 4. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR ZFN, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 5. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 6. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CELL LINE ENGINEERING, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 7. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR GENETIC ENGINEERING, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 8. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR DRUG DISCOVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 9. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR GENE-MODIFIED CELL THERAPY AND DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 10. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 11. GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 12. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR ACADEMICS & GOVERNMENT INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 13. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 14. GENOME EDITING/GENOME ENGINEERING MARKET VALUE FOR CONTRACT RESEARCH ORGANIZATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 15. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 16. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 17. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 18. NORTH AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 19. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 20. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 21. U.S GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 22. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 23. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 24. CANADA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 25. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 26. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 27. MEXICO GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 28. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 29. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 30. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 31. EUROPE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 32. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 33. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 34. GERMANY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 35. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 36. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 37. U.K GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 38. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 39. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 40. FRANCE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 41. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 42. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 43. ITALY GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 44. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 45. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 46. SPAIN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 47. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 48. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 49. ROE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 50. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 51. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 52. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 53. ASIA PACIFIC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 54. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 55. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 56. CHINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 57. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 58. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 59. INDIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 60. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 61. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 62. JAPAN GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 63. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 64. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 65. REST OF APAC GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 66. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 67. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 68. LATIN AMERICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 69. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 70. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 71. BRAZIL GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 72. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 73. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 74. ARGENTINA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 75. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 76. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 77. MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 78. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 79. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 80. SAUDI ARABIA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 81. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 82. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 83. UAE GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 84. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) CHART. 85. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 86. REST OF MIDDLE EAST AND AFRICA GENOME EDITING/GENOME ENGINEERING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) CHART. 87. GENSCRIPT BIOTECH CORPORATION : FINANCIALS CHART. 88. GENSCRIPT BIOTECH CORPORATION : PRODUCTS & SERVICES CHART. 89. GENSCRIPT BIOTECH CORPORATION : RECENT DEVELOPMENTS CHART. 90. AGLIENT TECHNOLOGIES, INC.: FINANCIALS CHART. 91. AGLIENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES CHART. 92. AGLIENT TECHNOLOGIES, INC.: RECENT DEVELOPMENTS CHART. 93. MERCK KGAA: FINANCIALS CHART. 94. MERCK KGAA: PRODUCTS & SERVICES CHART. 95. MERCK KGAA: RECENT DEVELOPMENTS CHART. 96. EDITAS MEDICINE, INC: FINANCIALS CHART. 97. EDITAS MEDICINE, INC: PRODUCTS & SERVICES CHART. 98. EDITAS MEDICINE, INC: RECENT DEVELOPMENTS CHART. 99. DANAHER CORPORATION: FINANCIALS CHART. 100. DANAHER CORPORATION: PRODUCTS & SERVICES CHART. 101. DANAHER CORPORATION: RECENT DEVELOPMENTS CHART. 102. CRISPR THERAPEUTICS AG: FINANCIALS CHART. 103. CRISPR THERAPEUTICS AG: PRODUCTS & SERVICES CHART. 104. CRISPR THERAPEUTICS AG: RECENT DEVELOPMENTS CHART. 105. LONZA GROUP LTD.: FINANCIALS CHART. 106. LONZA GROUP LTD.: PRODUCTS & SERVICES CHART. 107. LONZA GROUP LTD.: DEVELOPMENTS CHART. 108. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS CHART. 109. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES CHART. 110. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS CHART. 111. ORIGENE TECHNOLOGIES: FINANCIALS CHART. 112. ORIGENE TECHNOLOGIES: PRODUCTS & SERVICES CHART. 113. ORIGENE TECHNOLOGIES: RECENT DEVELOPMENTS CHART. 114. EUROFINS SCIENTIFIC: FINANCIALS CHART. 115. EUROFINS SCIENTIFIC: PRODUCTS & SERVICES CHART. 116. EUROFINS SCIENTIFIC: RECENT DEVELOPMENTS
Publisher: IHR Insights
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support